Corbion announced its acquisition of TerraVia Holdings on Sept. 29.
|Tjerk de Ruiter, CEO of Corbion|
“Actually, what makes us unique by taking a company on like TerraVia is that our capability could produce large-scale fermentations at low cost,” said Tjerk de Ruiter, CEO of Corbion, on Nov. 9.
Costs of algae-based oil potentially could become more comparable to palm kernel oil, he said.
“A palm kernel oil, you can check that on the market,” he said. “I think the pricing varies from $900 to $1,500 a ton. This technology will not replace oil. This technology will replace specific fractions of palm kernel that are much higher valued.”
Marcel Wubbolts, Ph.D., chief technology officer for Corbion, spoke about enzymes in bakery.
|Marcel Wubbolts, Ph.D., chief technology officer for Corbion|
“Enzymes are the catalysts of nature, and also in the portfolio of TerraVia, we are using enzymes as well, and we are engineering enzymes in algae to make our products fit better,” he said.
Other Corbion ingredients work to inhibit bacteria in meat products, such as by avoiding Listeria or Salmonella.
“We have great competencies there, and we are now also very excited about adding some of the AlgaVia products because some of the algae oils are also known to have antimicrobial effects,” Dr. Wubbolts said.
Under the strategy for 2018-2021, Corbion will aim for net annual sales growth of 2 percent to 4 percent in Ingredient Solutions. The goal includes annual sales growth of 1 percent to 3 percent in Food and 3 percent to 10 percent in Biochemicals. Corbion wants to maintain an EBITDA margin of greater than 19 percent in Ingredient Solutions.
Within Ingredient Solutions, Corbion plans to expand in Latin America in Bakery while targeting faster growing segments such as sweet goods and the food service channel in the United States. In Meat, Corbion will extend its antimicrobial/preservation product portfolio. In Biochemicals, the company will continue a portfolio approach based on lactic acid.
To support the growth initiatives, Corbion will invest more in research and development, where expenses as a percentage of sales will increase to 4 percent from 3 percent.